RCEN
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
Recce Pharmaceuticals Ltd
π¦πΊ ASX
π Overview
π Performance
π΅ Cost
π€ Advanced
π¨βπ©βπ§βπ¦ Community
π
N/A
Annual Growth
5 years average annual capital growth
π΅
$ 500
Minimum Order
Due to regulatory requirements
π
8
Pearlers Invested
Since January 2020
π Overview
Key information
π Fund Overview
Recce Pharmaceuticals Ltd - Ordinary Fully Paid Deferred
π Performance
Price History
N/A
1M
All Time
Graph
Table
Unsure how much or often to invest?
ποΈ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out βπ΅ Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out ββ±οΈ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out βπ΅ Costs
πΌ
N/A
Management Fee
Included in unit price, not charged by Pearler
πΈ
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πΈ Net fee calculatorπ€ Advanced information
Technical Info
π©βπ©βπ¦ Community Insights
How our community is investing
π Pearlers invested in RCEN
0
π Total Capital Earnings
N/A
π Average investment frequency
N/A
π΅ Average investment amount
N/A
β° Last time a customer invested in RCEN
N/A
RCEN investor breakdown
π΅ Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
πΆ Age of investors
18 - 25
26 - 34
35 - 90
π Legal gender of investors
Female
Male
Pearlers who invest in RCEN also invest in...
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.
π Performance (5Yr p.a)
-0.28%
π Share price
$0.35 AUD
π¦ LOGISTICS
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
π Performance (5Yr p.a)
8.32%
π Share price
$94.88 AUD
π¦πΊ AUSTRALIA
πΈ FINANCIALS
π HIGH PRICE GROWTH
𧱠MATERIALS
β³οΈ DIVERSIFIED
EBR Systems, Inc. engages in the development of implantable systems for wireless tissue stimulation. The company is headquartered in Sunnyvale, California. The company went IPO on 2021-11-24. The company is a medical device company developing the wireless stimulation endocardially cardiac resynchronization therapy (WiSE CRT) System, an implantable cardiac pacing system that stimulates endocardial heart tissue to correct heart rhythm conditions without using leads. This investigational device delivers left-ventricle endocardial pacing for CRT without wires or leads. The WiSE CRT System developed a new approach to cardiac pacing, aiming to transform CRT delivery and benefit patients who have not succeeded with conventional CRT. The company operates wholly owned subsidiaries in Australia (EBR Systems (AUST) Pty Ltd) and the United Kingdom (EBR Systems (UK) Limited), which conduct clinical trials and work on intellectual property development in their respective regions.
π Share price
$1.50 AUD
π©Ί HEALTH CARE
IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
π Performance (5Yr p.a)
19.83%
π Share price
$57.04 AUD
π HIGH PRICE GROWTH
πΊπΈ UNITED STATES
Arafura Rare Earths Ltd. engages in the exploration and development of mineral resource properties. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-11-05. The firm produces rare earth products from the Nolans Project. The Nolans Project consists of a mine, process plant, including beneficiation, extraction and separation plants, and related infrastructure to be constructed and located at the Nolans site, approximately 135 kilometers north of Alice Springs in Australia's Northern Territory. Its rare earth products are Neodymium-Praseodymium (NdPr) oxide, and Mixed middle-heavy rare earths (SEG/HRE) oxide. NdPr oxide is the Company's flagship product, which is used by magnet and magnet alloy customers. The Companyβs primary products from the Nolans project are rare earths, which are used in catalytic converters in automobiles, consumer electronics, energy efficiency lighting, optics, alloys, advanced ceramics and permanent magnets that enable e-mobility and renewable energy applications.
π Performance (5Yr p.a)
35.36%
π Share price
$0.15 AUD
βοΈ MINING
π HIGH PRICE GROWTH
Want more shares? Try these...
Recce Pharmaceuticals Ltd. is engaged in the research and development of pharmaceutical drugs that kill germs. The company is headquartered in Sydney, New South Wales. The company went IPO on 2016-01-15. The firm's anti-infective pipeline includes three broad-spectrum, synthetic polymer anti-infectives: RECCE 327 as an intravenous and topical therapy that is being developed for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms; RECCE 435 as an orally administered therapy for bacterial infections; and RECCE 529 for viral infections. Through their multi-layered mechanisms of action, the Company's anti-infectives have the potential to overcome the hypercellular mutation of bacteria and viruses. All RECCE compounds are water soluble at all pH levels in their liquid form.
π Performance (5Yr p.a)
-0.28%
π Share price
$0.35 AUD
π¦ LOGISTICS